Literature DB >> 1994896

The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi3(+)-pretreatment in the rat in vivo and in vitro. Are antioxidant properties of metallothionein more relevant than platinum binding?

P J Boogaard1, A Slikkerveer, J F Nagelkerke, G J Mulder.   

Abstract

Nephrotoxicity induced by cisplatin (CDDP) was reported to be reduced by Bi3(+)-pretreatment, which selectively induces renal metallothionein (MT). In the present study renal MT had increased to 250% of control in rats that received bismuth subnitrate (50 mumol/kg/day, orally) for 8 days. In vitro experiments demonstrated that the reduction of CDDP-induced toxicity is a renal effect: in proximal tubular cells (PTC) isolated from Bi3(+)-treated rats the toxicity of CDDP, and also of HgCl2, CdCl2 and p-aminophenol, was reduced as compared to PTC from untreated rats. In contrast to the reduction in CDDP, Hg2+ and Cd2+ toxicity, the reduction in p-aminophenol toxicity cannot be explained by the metal-binding properties of MT. MT was reported to act as a free radical scavenger, which may explain our observation since p-aminophenol toxicity is thought to be a consequence of the generation of oxygen radicals. In vivo experiments showed that the overall renal Pt-content as well as the Pt bound to renal MT is lower in Bi3(+)-pretreated rats than in untreated rats, 24 hr after administration of CDDP (12 mg/kg), suggesting that the reduction in nephrotoxicity is not due to increased binding of Pt2+ to renal MT. Renal superoxide dismutase (SOD) activity was increased in rats that had only received CDDP. Such a rise in SOD may result from peroxidative damage caused by exposure to CDDP. The fact that SOD was not elevated in rats that received Bi3+ prior to CDDP suggests that (i) peroxidation contributes to CDDP-induced nephrotoxicity and (ii) the anti-oxidant properties of MT are responsible for the reduction of this toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1994896     DOI: 10.1016/0006-2952(91)90533-b

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells.

Authors:  Yifan Hong; Yau-Tsz Lai; Godfrey Chi-Fung Chan; Hongzhe Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

Review 2.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.

Authors:  N Roosen; F Doz; K L Yeomans; D V Dougherty; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Protective Effect of D-Methionine on Body Weight Loss, Anorexia, and Nephrotoxicity in Cisplatin-Induced Chronic Toxicity in Rats.

Authors:  Ming-Tai Lin; Jiunn-Liang Ko; Te-Chung Liu; Pei-Tsen Chao; Chu-Chyn Ou
Journal:  Integr Cancer Ther       Date:  2018-02-11       Impact factor: 3.279

5.  Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms.

Authors:  Runming Wang; Suyu Wang; Shing Chan; Yuchuan Wang; Yufeng Zhang; Zhong Zuo; Godfrey Chi-Fung Chan; Hongyan Li; Hongzhe Sun
Journal:  iScience       Date:  2020-04-12

6.  Bismuth Reduces Cisplatin-Induced Nephrotoxicity Via Enhancing Glutathione Conjugation and Vesicular Transport.

Authors:  Hui Jiang; Yifan Hong; Guorong Fan
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.